[go: up one dir, main page]

MX2011007025A - Forma polimorfica de 5-cloro-n-{[(5s)-2-oxo-3-[4-(3-oxomorfolin-4- il)fenil]oxa-zolidin-5-il]-metil)tiofeno-2-carboxamida. - Google Patents

Forma polimorfica de 5-cloro-n-{[(5s)-2-oxo-3-[4-(3-oxomorfolin-4- il)fenil]oxa-zolidin-5-il]-metil)tiofeno-2-carboxamida.

Info

Publication number
MX2011007025A
MX2011007025A MX2011007025A MX2011007025A MX2011007025A MX 2011007025 A MX2011007025 A MX 2011007025A MX 2011007025 A MX2011007025 A MX 2011007025A MX 2011007025 A MX2011007025 A MX 2011007025A MX 2011007025 A MX2011007025 A MX 2011007025A
Authority
MX
Mexico
Prior art keywords
oxomorpholin
oxa
carboxamide
thiophene
oxo
Prior art date
Application number
MX2011007025A
Other languages
English (en)
Inventor
Gamini Weeratunga
Prabhudas Bodhuri
Original Assignee
Apotex Pharmachem Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Apotex Pharmachem Inc filed Critical Apotex Pharmachem Inc
Publication of MX2011007025A publication Critical patent/MX2011007025A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Se proporcionan una forma polimórfica de rivaroxaban, 5-cloro-N-{ [(5S)-2-oxo-3-[4-(3-oxomorfolin-4-il)fenil]oxa- zolidin-5-il]-metil) tiofeno-2-carboxamida (denominada APO-A), procesos para la preparación de la misma, y composiciones y formulaciones que comprenden la forma APO-A. También se proporcionan composiciones que comprenden una forma cristalina de rivaroxaban y solventes seleccionados a partir de cetonas C3 a C6, amidas C3 a C4 y mezclas de los mismos.
MX2011007025A 2008-12-31 2009-12-31 Forma polimorfica de 5-cloro-n-{[(5s)-2-oxo-3-[4-(3-oxomorfolin-4- il)fenil]oxa-zolidin-5-il]-metil)tiofeno-2-carboxamida. MX2011007025A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12/347,176 US20100168111A1 (en) 2008-12-31 2008-12-31 Polymorphic form of 5 chloro n {[(5s) 2 oxo 3 [4 (3 oxomorpholin 4 yl)phenyl]oxa-zolidin 5 yl]-methyl}thiophene 2 carboxamide
PCT/CA2009/001895 WO2010075631A1 (en) 2008-12-31 2009-12-31 Polymorphic form of 5-chloro-n-{[(5s)-2-oxo-3-[4-(3-oxomorpholin-4-yl)phenyl]oxa-zolidin-5-yl]-methyl}thiophene-2-carboxamide

Publications (1)

Publication Number Publication Date
MX2011007025A true MX2011007025A (es) 2011-09-01

Family

ID=42285699

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2011007025A MX2011007025A (es) 2008-12-31 2009-12-31 Forma polimorfica de 5-cloro-n-{[(5s)-2-oxo-3-[4-(3-oxomorfolin-4- il)fenil]oxa-zolidin-5-il]-metil)tiofeno-2-carboxamida.

Country Status (12)

Country Link
US (1) US20100168111A1 (es)
EP (1) EP2382209A4 (es)
JP (1) JP2012514010A (es)
KR (1) KR20110130395A (es)
CN (1) CN102292332A (es)
AU (1) AU2009335611A1 (es)
BR (1) BRPI0918704A2 (es)
CA (1) CA2748853A1 (es)
IL (1) IL213881A0 (es)
MX (1) MX2011007025A (es)
NZ (1) NZ593818A (es)
WO (1) WO2010075631A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7816355B1 (en) 2009-04-28 2010-10-19 Apotex Pharmachem Inc Processes for the preparation of rivaroxaban and intermediates thereof
WO2011012321A1 (en) 2009-07-31 2011-02-03 Krka, D.D., Novo Mesto Processes for crystallization of rivaroxaban
EP2573084A1 (en) 2011-09-22 2013-03-27 Enantia, S.L. Novel crystalline forms of rivaroxaban and processes for their preparation
HU230734B1 (hu) 2011-10-10 2017-12-28 EGIS Gyógyszergyár Nyrt Gyógyászati készítmény előállítására alkalmazható rivaroxaban kokristályok
WO2014096214A1 (en) 2012-12-21 2014-06-26 Farma Grs, D.O.O. A process for preparation of rivaroxaban
IN2014CH00290A (es) 2014-01-23 2015-08-14 Symed Labs Ltd
CN104211693B (zh) * 2014-08-07 2017-02-22 成都百裕制药股份有限公司 一种利伐沙班晶型及其制备方法与用途
CN105367563A (zh) * 2014-08-20 2016-03-02 中国医学科学院药物研究所 利伐沙班晶iv型物质及制备方法和其组合物与用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19962924A1 (de) * 1999-12-24 2001-07-05 Bayer Ag Substituierte Oxazolidinone und ihre Verwendung
DE10300111A1 (de) * 2003-01-07 2004-07-15 Bayer Healthcare Ag Verfahren zur Herstellung von 5-Chlor-N-({(5S)-2-oxo-3-[4-(3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidin-5-yl}-methyl)-2-thiophencarboxamid
DE102004002044A1 (de) * 2004-01-15 2005-08-04 Bayer Healthcare Ag Herstellverfahren
DE102004062475A1 (de) * 2004-12-24 2006-07-06 Bayer Healthcare Ag Feste, oral applizierbare pharmazeutische Darreichungsformen mit modifizierter Freisetzung
AU2006299126B2 (en) * 2005-10-04 2012-06-28 Bayer Intellectual Property Gmbh Novel polymorphous form and the amorphous form of 5-chloro-N-({(5S)-2-oxo-3-[4-(3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidine-5-yl}-methyl)-2-thiophene carboxamide
JP5389028B2 (ja) * 2007-08-14 2014-01-15 コンサート ファーマシューティカルズ インコーポレイテッド 置換オキサゾリジノン誘導体
DE102008028071A1 (de) * 2008-06-12 2009-12-17 Bayer Schering Pharma Aktiengesellschaft Neue Cokristall-Verbindung von Rivaroxaban und Malonsäure

Also Published As

Publication number Publication date
KR20110130395A (ko) 2011-12-05
CN102292332A (zh) 2011-12-21
EP2382209A1 (en) 2011-11-02
JP2012514010A (ja) 2012-06-21
AU2009335611A1 (en) 2011-07-21
WO2010075631A1 (en) 2010-07-08
BRPI0918704A2 (pt) 2019-09-03
CA2748853A1 (en) 2010-07-08
NZ593818A (en) 2013-12-20
EP2382209A4 (en) 2012-08-01
US20100168111A1 (en) 2010-07-01
IL213881A0 (en) 2011-07-31

Similar Documents

Publication Publication Date Title
MX2011007025A (es) Forma polimorfica de 5-cloro-n-{[(5s)-2-oxo-3-[4-(3-oxomorfolin-4- il)fenil]oxa-zolidin-5-il]-metil)tiofeno-2-carboxamida.
MX2010001754A (es) Derivados de azepina como inhibidores de gamma secretasa.
MX341197B (es) Compuestos de isoindol 5 - sustituidos.
EA033332B1 (ru) Способ получения метил {(2s,3r)-1-[(2s)-2-{5-[(2r,5r)-1-{3,5-дифтор-4-[4-(4-фторфенил)пиперидин-1-ил]фенил}-5-(6-фтор-2-{(2s)-1-[n-(метоксикарбонил)-о-метил-l-треонил]пирролидин-2-ил}-1н-бензимидазол-5-ил)пирролидин-2-ил]-6-фтор-1н-бензимидазол-2-ил}пирролидин-1-ил]-3-метокси-1-оксобутан-2-ил} карбамата
DK2023958T4 (da) Farmaceutisk produkt til intraoral levering af nikotin omfattende trometamol som buffermiddel
PE20091565A1 (es) Derivados de 2-pirazinona como inhibidores de la elastasa de los neutrofilos
GEP20125666B (en) HYDROXYMETHYL PYRROLIDINES AS β3 ADRENERGIC RECEPTOR AGONISTS
MX2010009610A (es) Formas de cristal de 5-[3-(2,5-dicloro-4,6-dimetil-1-oxi-piridin-3 -il)-[1,2,4]oxadiazol-5-il]-3-nitrobenceno-1,2-diol.
PE20191204A1 (es) Modificador del sabor dulce
MA32383B1 (fr) DÉRIVÉS D'INDAZOLES à SUBSTITUTIONS PHÉNYLE ET BENZODIOXYNYLE
NO20084278L (no) Bezothiazol derivatives as beta2 adrenoreceptor agonists
ATE545645T1 (de) Neue cokristall-verbindung von rivaroxaban und malonsäure
EP2649033A4 (en) COMPOSITIONS AND METHODS OF STABILIZING COMPONENTS BY 2,4-PENTANDONE COMPOUNDS
WO2009147170A3 (en) Drug combinations comprising a dgat inhibitor and a ppar-agonist
IL210483A0 (en) Pharmaceutical compositions comprising 5-chlooro-n-({(5s)-2-oxo-3-[4-(3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidin-5-yl}-methyl)-2-thiophencarboxamid
EA201201082A1 (ru) Фармацевтическая композиция, содержащая n-(2-хлор-6-метилфенил)-2-[[6-[4-(2-гидроксиэтил)-1-пиперазинил]-2-метил-4-пиримидинил]амино]-5-тиазолкарбоксамид
MY151211A (en) 4-[2-(2-fluorophenoxymethyl)phenyl]piperidine compounds
ZA200806891B (en) Aminoacyl prodrug derivatives and medicaments for the treatment of thromboembolitic disorders
TW200942529A (en) Pyrrolidinyl derivatives and uses thereof
NO20080750L (no) (Indol-3-YL)-heterocykelderivater som agonister av cannabinoid CB1 reseptor
MX2012000685A (es) Compuesto de 3-fenoximetilpirrolidina.
MX2009001977A (es) Derivados profarmacologicos de aminoacilo y medicamentos para el tratamiento de enfermedades tromboembolicas.
IN2014DN06122A (es)
NZ599070A (en) Heterobicycle-substituted azolyl benzene fungicides
MX2009008221A (es) Antagonista de receptor de cromeno s1p1.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal